CN113424065A - 对手术后不良事件进行的诊断或预后 - Google Patents

对手术后不良事件进行的诊断或预后 Download PDF

Info

Publication number
CN113424065A
CN113424065A CN202080014273.5A CN202080014273A CN113424065A CN 113424065 A CN113424065 A CN 113424065A CN 202080014273 A CN202080014273 A CN 202080014273A CN 113424065 A CN113424065 A CN 113424065A
Authority
CN
China
Prior art keywords
level
sample
fragment
hours
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080014273.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·楚
亨利克·安德森
D·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lin Xueping University Hospital
BRAHMS GmbH
Original Assignee
Lin Xueping University Hospital
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Xueping University Hospital, BRAHMS GmbH filed Critical Lin Xueping University Hospital
Publication of CN113424065A publication Critical patent/CN113424065A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080014273.5A 2019-02-21 2020-02-21 对手术后不良事件进行的诊断或预后 Pending CN113424065A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19020082 2019-02-21
EP19020082.4 2019-02-21
PCT/EP2020/054652 WO2020169819A1 (en) 2019-02-21 2020-02-21 Diagnosis or prognosis of postsurgical adverse events

Publications (1)

Publication Number Publication Date
CN113424065A true CN113424065A (zh) 2021-09-21

Family

ID=65529223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014273.5A Pending CN113424065A (zh) 2019-02-21 2020-02-21 对手术后不良事件进行的诊断或预后

Country Status (7)

Country Link
US (1) US20220187313A1 (https=)
EP (1) EP3928099A1 (https=)
JP (2) JP2022521390A (https=)
CN (1) CN113424065A (https=)
BR (1) BR112021016597A2 (https=)
CA (2) CA3295270A1 (https=)
WO (1) WO2020169819A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240221958A1 (en) * 2021-04-30 2024-07-04 Roche Diagnostics Operations, Inc. Pct marker panels for early detection of sepsis
WO2022229438A2 (en) * 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Il6 marker panels for early detection of sepsis
EP4351636A4 (en) * 2021-06-02 2025-04-23 Washington University Systems and methods for multimodal analysis of surgical drain fluid using interchangeable and customizable nucleic acid based tests
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
KR20250077078A (ko) * 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심장 트로포닌 수치를 예측하기 위한 방법 및 장치
KR20250077079A (ko) 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심근 손상을 예측하기 위한 방법 및 장치
WO2026013199A1 (en) 2024-07-12 2026-01-15 Cezanne S.A.S. Clinical immunoassay with early signal measurement
KR102750097B1 (ko) * 2024-07-29 2025-01-03 가천대학교 산학협력단 심혈관 시술 이후 환자의 합병증 예측 및 추적 관리 시스템 및 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213746A1 (en) * 2006-11-09 2008-09-04 Leong Loke Ng Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin
CN101611314A (zh) * 2006-12-20 2009-12-23 布拉姆斯股份公司 利用新颖标志物CT-proADM进行诊断和危险分层
US20120003751A1 (en) * 2008-10-07 2012-01-05 B.R.A.H.M.S. Gmbh Biomarker for the prediction of first adverse events
WO2018141840A1 (en) * 2017-02-02 2018-08-09 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
ATE312351T1 (de) 2004-02-13 2005-12-15 Brahms Ag Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens
WO2014018464A1 (en) * 2012-07-23 2014-01-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
JP6855118B2 (ja) * 2017-03-14 2021-04-07 東ソー株式会社 全身状態の良不良を評価するための情報を提供する方法及び測定試薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213746A1 (en) * 2006-11-09 2008-09-04 Leong Loke Ng Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin
CN101611314A (zh) * 2006-12-20 2009-12-23 布拉姆斯股份公司 利用新颖标志物CT-proADM进行诊断和危险分层
US20120003751A1 (en) * 2008-10-07 2012-01-05 B.R.A.H.M.S. Gmbh Biomarker for the prediction of first adverse events
WO2018141840A1 (en) * 2017-02-02 2018-08-09 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A DI FILIPPO: "Procalcitonin as an early marker of postoperative infectious complications", 《MINERVA CHIR . 》, vol. 57, no. 1, 28 February 2002 (2002-02-28), pages 59 - 62 *
CESAR HENRIQUEZ-CAMACHO ET AL: "Biomarkers for sepsis", 《BIOMED RESEARCH INTERNATIONAL》, 30 March 2014 (2014-03-30), pages 1 - 6, XP008173034, DOI: 10.1155/2014/547818 *
J B LECHARNY: "Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery", 《CRIT CARE MED .》, vol. 29, no. 2, 28 February 2001 (2001-02-28), pages 323 - 325, XP055698888, DOI: 10.1097/00003246-200102000-00019 *

Also Published As

Publication number Publication date
JP2025019061A (ja) 2025-02-06
BR112021016597A2 (pt) 2021-11-03
CA3126202A1 (en) 2020-08-27
CA3295270A1 (en) 2026-03-02
US20220187313A1 (en) 2022-06-16
JP2022521390A (ja) 2022-04-07
WO2020169819A1 (en) 2020-08-27
EP3928099A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
CN113424065A (zh) 对手术后不良事件进行的诊断或预后
CN111630381B (zh) 基于pro-adm的抗生素疗法指导
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
US20240393352A1 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
RU2820944C2 (ru) Проадм для прогнозирования риска состояния, требующего госпитализации, у пациентов с симптомами инфекционного заболевания
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment
HK40030378A (zh) 基於pro-adm的抗生素疗法指导

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination